This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Should OShares FTSE U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for OUSA
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Honeywell (HON) and Morgan Stanley (MS).
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
by Zacks Equity Research
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress
by Swarup Gupta
The Dow experienced a particularly volatile week as earnings results took center stage.
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
by Zacks Equity Research
Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.
3 Dividend ETFs With High Inflows in April
by Zacks Equity Research
Consider these three dividend ETFs to fend off growing market uncertainty.
Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better
by Zacks Equity Research
Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.
New Construction Data, Q1 Earnings In Focus
by Zacks Equity Research
New Construction Data, Q1 Earnings In Focus
Tax Day Not So Taxing (for Corporations, Housing)
by Mark Vickery
Strength in Q1 earnings season, at least in these early stages, has helped bolster market indexes. This continues ahead of Tuesday's market open.
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
J&J (JNJ) Beats on Q1 Earnings & Sales, Ups 2018 Sales View
by Zacks Equity Research
J&J (JNJ) beat estimates for both earnings and sales in the first quarter of 2018. It maintained the previously issued earnings guidance for 2018 while increasing the sales range.
5 of the Best Big Cap Earnings Charts
by Tracey Ryniec
These big cap companies almost always beat the estimate on earnings but will that change in 2018?
Here's Why Geron Stock Surged More Than 90% in 6 Months
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Karyopharm's Myeloma Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.
4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings
by Tirthankar Chakraborty
The recent tax code overhaul and a strengthening economy could certainly help blue-chip companies make more money this upcoming earnings season.
4 Drug/Biotech Stocks to Buy Ahead of World Health Day
by Indrajit Bandyopadhyay
Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
by Zacks Equity Research
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
Wall Street Brushes Off Trade War Fears: Top 5 Gainers
by Tirthankar Chakraborty
The Dow climbed more than 700 points after investors downplayed fears over tariffs announced by both China and the United States.
Allergan's Vraylar Meets Endpoints in Bipolar I Phase III
by Zacks Equity Research
Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.